Yarrow Bioscience (YARW) Accumulated Expenses (2016 - 2026)

Yarrow Bioscience (YARW) has 11 years of Accumulated Expenses data on file, last reported at $86000.0 in Q1 2026.

• Quarterly Accumulated Expenses fell 98.75% year-over-year to $86000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86000.0 (down 98.75% YoY) and the FY2025 annual result came in at $941000.0, down 34.1% from the prior year.
• Accumulated Expenses eased to $86000.0 in Q1 2026, from $941000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $6.9 million in Q1 2025 to a low of $86000.0 in Q1 2026.
• A 5-year average of $2.7 million and a median of $2.3 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 506.34% — and 2026, when it plunged 98.75%.
• Tracing YARW's Accumulated Expenses over 5 years: stood at $2.4 million in 2022, then soared by 73.65% to $4.1 million in 2023, then slumped by 65.33% to $1.4 million in 2024, then plunged by 34.1% to $941000.0 in 2025, then tumbled by 90.86% to $86000.0 in 2026.
• The last three Accumulated Expenses figures came in at $86000.0 (Q1 2026), $941000.0 (Q4 2025), and $3.6 million (Q2 2025), per Business Quant data.